Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Burning Rock Biotech Ltd

Healthcare US BNR

8.52USD
0.96(12.70%)

Last update at 2026-06-24T20:00:00Z

Day Range

7.638.52
LowHigh

52 Week Range

2.1841.72
LowHigh

Fundamentals

  • Previous Close 7.56
  • Market Cap222.33M
  • Volume62042
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.45800M
  • Revenue TTM539.57M
  • Revenue Per Share TTM50.03
  • Gross Profit TTM 402.91M
  • Diluted EPS TTM-0.75

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -52.32450M -340.74100M -651.30100M -969.24800M -795.79800M
Minority interest - - - - -
Net income -53.83810M -346.62600M -653.68900M -971.23300M -796.69700M
Selling general administrative - 261.64M 437.82M 568.28M 490.26M
Selling and marketing expenses - 190.90M 247.71M 370.29M 303.10M
Gross profit 391.94M 362.40M 363.23M 380.04M 364.15M
Reconciled depreciation - 52.20M 133.40M 124.10M 47.77M
Ebit -53.35075M -322.43200M -651.30100M -980.40700M -797.06400M
Ebitda -43.05414M -270.23200M -517.90100M -981.95600M -793.40800M
Depreciation and amortization 10.30M 52.20M 133.40M -1.54900M 3.66M
Non operating income net other - - - - -
Operating income -53.35075M -357.55900M -669.32100M -980.40700M -797.06400M
Other operating expenses 578.22M 873.38M 1206.76M 1543.64M 1304.93M
Interest expense 0.03M - 0.00000M -11.15900M 1.54M
Tax provision - 5.88M 3.22M 1.99M 0.90M
Interest income - 12.21M 15.26M 9.46M 3.46M
Net interest income - 12.21M 15.26M 9.46M 1.92M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.51M 5.88M 2.39M 1.99M 0.90M
Total revenue 524.87M 515.82M 537.43M 563.24M 507.86M
Total operating expenses 445.29M 719.96M 1032.55M 1360.45M 1161.21M
Cost of revenue 132.93M 153.42M 174.21M 183.20M 143.72M
Total other income expense net 1.03M 16.82M 18.02M 11.16M 1.27M
Discontinued operations - - - - -
Net income from continuing ops - -346.62600M -707.70100M -971.23300M -796.69700M
Net income applicable to common shares - - - -971.23300M -796.69700M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 820.90M 885.30M 1040.00M 1587.47M 2278.59M
Intangible assets - 0.42M 0.96M 0.16M 5.15M
Earning assets - - - - -
Other current assets 18.62M 29.56M 2.80M 51.46M 60.28M
Total liab 285.29M 304.48M 271.59M 429.13M 433.28M
Total stockholder equity 535.60M 580.83M 768.41M 1158.34M 1845.31M
Deferred long term liab - - - - -
Other current liab 81.50M 75.04M 104.94M 173.83M 127.89M
Common stock 0.14M 0.14M 0.14M 0.14M 0.14M
Capital stock - 0.14M 0.14M 0.14M 0.14M
Retained earnings -4258.31693M -4200.26100M -3853.63500M -3199.94600M -2228.71300M
Other liab - - - 4.12M 11.78M
Good will 0.28M - - 1.82M -
Other assets 0.00001M - - 26.00M 45.14M
Cash 481.39M 519.85M 615.10M 905.45M 1431.32M
Cash and equivalents - - - - -
Total current liabilities 247.14M 266.30M 263.36M 411.45M 372.18M
Current deferred revenue 107.89M 118.49M 131.73M 149.44M 143.84M
Net debt -438.24691M -467.52800M -602.77200M -854.66400M -1344.63200M
Short term debt 16.97M 24.57M 8.63M 37.24M 37.37M
Short long term debt - - - - 2.37M
Short long term debt total 43.15M 52.32M 12.32M 50.79M 86.69M
Other stockholder equity 4956.02M 4938.99M 4783.44M 4523.87M 4280.96M
Property plant equipment - - - 300.03M 406.44M
Total current assets 739.06M 776.62M 884.10M 1258.76M 1820.95M
Long term investments - 0.00000M 0.34M 0.69M 0.91M
Net tangible assets - - - 1156.36M 1840.16M
Short term investments - 6.14M 13.40M 0.00000M 63.76M
Net receivables 182.03M 173.45M 167.81M 151.71M 134.59M
Long term debt - - - - -
Inventory 57.01M 53.76M 69.02M 130.32M 123.21M
Accounts payable 40.77M 33.75M 18.06M 50.95M 63.08M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -162.24024M -158.04800M -161.53300M -165.72200M -207.06900M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 7.64M 7.93M 5.09M 26.00M 45.14M
Deferred long term asset charges - - - - -
Non current assets total 81.84M 108.69M 155.91M 328.70M 457.64M
Capital lease obligations - 52.32M 12.32M 50.79M 84.31M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -4.41200M -14.00500M -7.46300M 81.70M -30.42000M
Change to liabilities - - 22.06M 63.10M 49.98M
Total cashflows from investing activities -4.41200M -9.30000M -7.46300M 81.70M -109.31200M
Net borrowings 0.00000M 0.00000M -2.37000M -44.80600M -20.59400M
Total cash from financing activities -0.07200M -48.83200M -86.23800M -52.89900M 2165.72M
Change to operating activities - - 30.60M -8.73200M 109.73M
Net income -346.62600M -653.68900M -971.23300M -796.69700M -407.23500M
Change in cash -93.05400M -310.05200M -513.84400M -486.09400M 1826.96M
Begin period cash flow 615.22M 925.27M 1439.11M 1925.21M 98.24M
End period cash flow 522.16M 615.22M 925.27M 1439.11M 1925.21M
Total cash from operating activities -92.26100M -255.78300M -456.80800M -477.88600M -73.54300M
Issuance of capital stock - - 0.00000M 0.00000M 2121.85M
Depreciation 52.20M 133.40M 124.10M 47.77M 33.31M
Other cashflows from investing activities 1.01M -1.19600M - 81.70M -109.31200M
Dividends paid - - - - -360.44100M
Change to inventory 2.51M 57.28M 11.20M -66.99900M -9.44400M
Change to account receivables -26.79900M -12.38600M -21.50500M -18.93000M -13.04200M
Sale purchase of stock -0.07200M -6.97700M -71.83400M -4.27000M -3.50000M
Other cashflows from financing activities - -41.85500M -12.03400M -3.82300M 721.58M
Change to netincome - - 401.49M 318.81M 188.29M
Capital expenditures 5.98M 9.38M 62.03M 213.45M 79.54M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -36.53200M -52.15700M 6.33M -62.39500M 112.10M
Stock based compensation 155.62M 260.72M 326.78M 282.43M 173.22M
Other non cash items 83.08M 55.94M 57.22M 35.61M 15.07M
Free cash flow -98.23800M -265.16700M -518.83900M -691.33400M -153.08200M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BNR
Burning Rock Biotech Ltd		 0.96 12.70% 8.52 - - 0.41 2.91 2.08 -0.1745
TMO
Thermo Fisher Scientific Inc		 18.06 3.85% 487.41 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 8.93 4.99% 187.90 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 4.59 3.62% 131.26 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 8.64 1.60% 549.95 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.

Burning Rock Biotech Ltd

No. 5, Xingdao Ring Road North, Guangzhou, China, 510005

Key Executives

Name Title Year Born
Dr. Shaokun Chuai Chief Scientific Officer & Director 1979
Mr. Yusheng Han Founder, Chairman & CEO 1979
Mr. Jinxiang Li CFO, Compliance Officer & Director 1985
Dr. Zhihong Zhang Chief Technology Officer 1976
Mr. Hao Liu Sr. Advisor 1974
Dr. Zhihong Zhang CTO & Director 1976
Mr. Hao Liu Senior Advisor 1974
Ms. Xiaozhi Hu Senior Director of Finance 1984
Dr. Xinru Mao Head of Pharma Biomarker & CDx Service and International Diagnostics Division NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.